Olodaterol 5 and 10 µg delivered once daily via the Respimat inhaler provided statistically significant improvements in lung function when compared to a placebo, according to study results presented at the 2013 European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.
The findings, from one set of 48-week, Phase 3 pivotal studies (NCT00782210) and (NCT00782509) were sponsored by Boehringer Ingelheim Pharmaceuticals.
In a second set of 48-week studies (NCT00793624) and (NCT00796653), the same dose and delivery of olodaterol provided comparable improvements in lung function compared to 12 µg formoterol twice daily in COPD patients. After 24 weeks of treatment, both doses of olodaterol and formoterol provided statistically significant improvements in FEV1 AUC0-3.
“Despite advances in the treatment of COPD, there remains a significant need to reduce the burden of COPD on patients’ lives,” said lead study author Gary T. Ferguson, MD, of the Pulmonary Research Institute of Southeast Michigan, Livonia, Michigan.
“We are excited about these data because we see that the lung function improvements shown with olodaterol may translate into patient-related benefits over and above those seen with usual care, and these improvements on top of permitted bronchodilator therapies makes these positive results even more noteworthy.”
